OTCMKTS:SWTUY SWEDISH ORPHAN/S (SWTUY) Stock Price, News & Analysis $24.38 -0.29 (-1.18%) As of 04/9/2019 Add Compare Share Share Stock Analysis Stock Analysis About SWEDISH ORPHAN/S Stock (OTCMKTS:SWTUY) Get SWEDISH ORPHAN/S alerts:Sign Up Key Stats Today's Range$24.38▼$24.3850-Day Range$24.38▼$24.3852-Week Range$18.50▼$31.96Volume200 shsAverage Volume1,665 shsMarket Capitalization$6.64 billionP/E Ratio48.76Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Swedish Orphan Biovitrum AB, commonly known as Sobi, is a biopharmaceutical company focused on developing and providing treatments for people with rare and debilitating diseases. Its work includes research and development, manufacturing, and commercialization of specialty medicines. The company’s areas of focus include rare hematologic and immunologic conditions, as well as selected metabolic diseases. Its portfolio includes therapies for disorders such as hemophilia and other rare blood conditions, alongside treatments for inflammatory and immune-related diseases. Based in Stockholm, Sweden, Sobi serves patients and healthcare providers in markets around the world. The company was formed in 2010 when Swedish Orphan acquired Biovitrum, bringing together the two businesses under the Swedish Orphan Biovitrum name.AI Generated. May Contain Errors. Read More Receive SWTUY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SWEDISH ORPHAN/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SWTUY Stock News HeadlinesSwedish Orphan Biovitrum : Late-breaking Phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinuradOctober 29, 2026 | marketscreener.comMSwedish Orphan Biovitrum AB: New analysis shows Tryngolza (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemiaMay 26, 2026 | finanznachrichten.deUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 15 at 1:00 AM | Digest Publishing (Ad)Swedish Orphan Biovitrum Receives Health Canada Approval for EMPAVELI (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGNApril 28, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: EMA validates indication extension application for Tryngolza (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)March 31, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026February 3, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi Receives European Commission Approval for Aspaveli (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGNJanuary 16, 2026 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlookJanuary 15, 2026 | finanznachrichten.deSee More Headlines SWTUY Stock Analysis - Frequently Asked Questions How have SWTUY shares performed this year? SWEDISH ORPHAN/S's stock was trading at $24.38 on January 1st, 2026. Since then, SWTUY shares have increased by 0.0% and is now trading at $24.38. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Private Households Sub-IndustryN/A Current SymbolOTCMKTS:SWTUY Previous SymbolNASDAQ:SWTUY CIKN/A Webwww.sobi.com Phone46-0-869-720-00FaxN/AEmployees902Year Founded2010Profitability EPS (Trailing Twelve Months)$0.50 Trailing P/E Ratio48.76 Forward P/E Ratio16.93 P/E Growth1.3Net Income$134.73 million Net Margins25.75% Pretax MarginN/A Return on Equity29.63% Return on Assets18.74% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$763.19 million Price / Sales8.71 Cash Flow$0.70 per share Price / Cash Flow34.66 Book Value$2.88 per share Price / Book8.47Miscellaneous Outstanding Shares272,508,000Free FloatN/AMarket Cap$6.64 billion OptionableNot Optionable Beta1.81 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:SWTUY) was last updated on 4/9/2019 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SWEDISH ORPHAN/S Please log in to your account or sign up in order to add this asset to your watchlist. Share SWEDISH ORPHAN/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.